The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Biohaven wasn’t one of them. The 10 stocks that made the cut ...

News of a big and important regulator's move was the electricity that powered Biohaven (NYSE: BHVN) stock to an 11%-plus gain on the second trading day of the week. Its leading investigational drug is ...

Deutsche Bank analyst David Hoang initiated coverage on Biohaven with a Buy rating and a price target of $65.00 ... The company's stock movement reflects investor confidence in its strategic ...

Biohaven (BHVN) is jumping 10% after the FDA agreed to review the company’s potential treatment for a rare disease.

Before market open, Biohaven announced that the U.S. Food and ... That alone is worth considering its stock for a buy. Eric Volkman has no position in any of the stocks mentioned.

Biohaven (BHVN) is jumping 10% after the FDA ... If you are looking for an AI stock that is more promising than BHVN but that trades at less than 5 times its earnings, check out our report about ...

Deutsche Bank analyst David Hoang initiated coverage on Biohaven with a Buy rating and a price target of $65.00 ... a troriluzole Marketing Authorization Application. The company's stock movement ...

Before market open, Biohaven announced that the U.S. Food and ... That alone is worth considering its stock for a buy. Ever feel like you missed the boat in buying the most successful stocks?

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biohaven Ltd. (BHVN – Research Report), ...